Serum proteomics for gastric cancer

Clinica Chimica Acta

Volumn 431, Issue , 2014, Pages 179-184

  Liu, Wentao ^a   Yang, Qiumeng ^a   Liu, Bingya ^a   Zhu, Zhenggang ^a  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

Biomarker; Gastric cancer; Proteomics; Serum

Indexed keywords

TUMOR MARKER; TUMOR PROTEIN;

ANALYTIC METHOD; BIOINFORMATICS; BLOOD ANALYSIS; CANCER RESEARCH; EXPERIMENTAL DESIGN; EXTRACTION; GENERAL DEVICE; HUMAN; LIQUID CHIP SYSTEM; MAGNETIC BEAD; MASS SPECTROMETRY; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN ISOLATION; PROTEIN STRUCTURE; PROTEOMICS; RELIABILITY; REVIEW; STOMACH CANCER; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; VALIDATION PROCESS; ANIMAL; BLOOD; GENETICS; PROCEDURES; STOMACH TUMOR;

ANIMALS; HUMANS; NEOPLASM PROTEINS; PROTEOMICS; STOMACH NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84896696382     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2014.02.001     Document Type: Review

References (75)

1. Jemal A., Bray F., Center M.M., Ferlay J., Ward E., Forman D. Global cancer statistics. CA Cancer J Clin 2011, 61:69-90.
2. Ebert M.P., Malfertheiner P. Review article: pathogenesis of sporadic and familial gastric cancer-implications for clinical management and cancer prevention. Aliment Pharmacol Ther 2002, 16:1059-1066.
3. Ucar E., Semerci E., Ustun H., Yetim T., Huzmeli C., Gullu M. Prognostic value of preoperative CEA, CA 19-9, CA 72-4, and AFP levels in gastric cancer. Adv Ther 2008, 25:1075-1084.
4. Marrelli D., Roviello F., De Stefano A., Farnetani M., Garosi L., Messano A., et al. Prognostic significance of CEA, CA 19-9 and CA 72-4 preoperative serum levels in gastric carcinoma. Oncology 1999, 57:55-62.
5. Ishigami S., Natsugoe S., Hokita S., Che X., Tokuda K., Nakajo A., et al. Clinical importance of preoperative carcinoembryonic antigen and carbohydrate antigen 19-9 levels in gastric cancer. Journal of clinical gastroenterology 2001, 32:41-44.
6. Liu X., Cai H., Wang Y. Prognostic significance of tumor markers in T4a gastric cancer. World J Surg Oncol 2012, 10:68.
7. Wasinger V.C., Cordwell S.J., Cerpa-Poljak A., Yan J.X., Gooley A.A., Wilkins M.R., et al. Progress with gene-product mapping of the Mollicutes: Mycoplasma genitalium. Electrophoresis 1995, 16:1090-1094.
8. Wu C., Luo Z., Chen X., Wu C., Yao D., Zhao P., et al. Two-dimensional differential in-gel electrophoresis for identification of gastric cancer-specific protein markers. Oncology reports 2009, 21:1429-1437.
9. Tseng C.W., Yang J.C., Chen C.N., Huang H.C., Chuang K.N., Lin C.C., et al. Identification of 14-3-3beta in human gastric cancer cells and its potency as a diagnostic and prognostic biomarker. Proteomics 2011, 11:2423-2439.
10. Wu W., Juan W.C., Liang C.R., Yeoh K.G., So J., Chung M.C. S100A9, GIF and AAT as potential combinatorial biomarkers in gastric cancer diagnosis and prognosis. Proteomics Clin Appl 2012, 6:152-162.
11. Li X., Gong Y., Wang Y., Wu S., Cai Y., He P., et al. Comparison of alternative analytical techniques for the characterisation of the human serum proteome in HUPO Plasma Proteome Project. Proteomics 2005, 5:3423-3441.
12. Juan H.F., Chen J.H., Hsu W.T., Huang S.C., Chen S.T., Yi-Chung Lin J., et al. Identification of tumor-associated plasma biomarkers using proteomic techniques: from mouse to human. Proteomics 2004, 4:2766-2775.
13. Ebert M.P., Kruger S., Fogeron M.L., Lamer S., Chen J., Pross M., et al. Overexpression of cathepsin B in gastric cancer identified by proteome analysis. Proteomics 2005, 5:1693-1704.
14. Liu W., Liu B., Xin L., Zhang Y., Chen X., Zhu Z., et al. Down-regulated expression of complement factor I: a potential suppressive protein for gastric cancer identified by serum proteome analysis. Clinica chimica acta;international journal of clinical chemistry 2007, 377:119-126.
15. Tonge R., Shaw J., Middleton B., Rowlinson R., Rayner S., Young J., et al. Validation and development of fluorescence two-dimensional differential gel electrophoresis proteomics technology. Proteomics 2001, 1:377-396.
16. Qin S., Ferdinand A.S., Richie J.P., O'Leary M.P., Mok S.C., Liu B.C. Chromatofocusing fractionation and two-dimensional difference gel electrophoresis for low abundance serum proteins. Proteomics 2005, 5:3183-3192.
17. Yu K.H., Rustgi A.K., Blair I.A. Characterization of proteins in human pancreatic cancer serum using differential gel electrophoresis and tandem mass spectrometry. J Proteome Res 2005, 4:1742-1751.
18. Liu W., Liu B., Cai Q., Li J., Chen X., Zhu Z. Proteomic identification of serum biomarkers for gastric cancer using multi-dimensional liquid chromatography and 2D differential gel electrophoresis. Clin Chim Acta 2012, 413:1098-1106.
19. Bones J., Byrne J.C., O'Donoghue N., McManus C., Scaife C., Boissin H., et al. Glycomic and glycoproteomic analysis of serum from patients with stomach cancer reveals potential markers arising from host defense response mechanisms. Journal of proteome research 2011, 10:1246-1265.
20. Hutchens T.W., Yip T. New desorption strategies for the mass spectrometric analysis of macromolecules. Rapid Commun Mass Spectrom 1993, 7:576-580.
21. Petricoin E.F., Ardekani A.M., Hitt B.A., Levine P.J., Fusaro V.A., Steinberg S.M., et al. Use of proteomic patterns in serum to identify ovarian cancer. Lancet 2002, 359:572-577.
22. Celis J.E., Gromov P., Cabezon T., Moreira J.M., Ambartsumian N., Sandelin K., et al. Proteomic characterization of the interstitial fluid perfusing the breast tumor microenvironment: a novel resource for biomarker and therapeutic target discovery. Molecular & cellular proteomics : MCP 2004, 3:327-344.
23. Skytt A., Thysell E., Stattin P., Stenman U.H., Antti H., Wikstrom P. SELDI-TOF MS versus prostate specific antigen analysis of prospective plasma samples in a nested case-control study of prostate cancer. Int J Cancer 2007, 121:615-620.
24. Ebert M.P., Meuer J., Wiemer J.C., Schulz H.U., Reymond M.A., Traugott U., et al. Identification of gastric cancer patients by serum protein profiling. Journal of proteome research 2004, 3:1261-1266.
25. Qian H.G., Shen J., Ma H., Ma H.C., Su Y.H., Hao C.Y., et al. Preliminary study on proteomics of gastric carcinoma and its clinical significance. World journal of gastroenterology : WJG 2005, 11:6249-6253.
26. Kojima T., Yoshikawa K., Saga S., Yamada T., Kure S., Matsui T., et al. Detection of elevated proteins in peritoneal dissemination of gastric cancer by analyzing mass spectra data of serum proteins. The Journal of surgical research 2009, 155:13-17.
27. Su Y., Shen J., Qian H., Ma H., Ji J., Ma H., et al. Diagnosis of gastric cancer using decision tree classification of mass spectral data. Cancer science 2007, 98:37-43.
28. Liang Y., Fang M., Li J., Liu C.B., Rudd J.A., Kung H.F., et al. Serum proteomic patterns for gastric lesions as revealed by SELDI mass spectrometry. Experimental and molecular pathology 2006, 81:176-180.
29. Liu C., Pan C., Shen J., Wang H., Yong L. Identification of serum amyloid A in the serum of gastric cancer patients by protein expression profiling. Oncol Lett 2012, 3:1259-1262.
30. Mohri Y., Mohri T., Wei W., Qi Y.J., Martin A., Miki C., et al. Identification of macrophage migration inhibitory factor and human neutrophil peptides 1-3 as potential biomarkers for gastric cancer. British journal of cancer 2009, 101:295-302.
31. Leung S.M., Pitts R.L. A novel approach using MALDI-TOF/TOF mass spectrometry and prestructured sample supports (AnchorChip Technology) for proteomic profiling and protein identification. Methods Mol Biol 2008, 441:57-70.
32. Kojima K., Asmellash S., Klug C.A., Grizzle W.E., Mobley J.A., Christein J.D. Applying proteomic-based biomarker tools for the accurate diagnosis of pancreatic cancer. J Gastrointest Surg 2008, 12:1683-1690.
33. Fan N.J., Gao C.F., Wang X.L., Zhao G., Liu Q.Y., Zhang Y.Y., et al. Serum peptidome patterns of colorectal cancer based on magnetic bead separation and MALDI-TOF mass spectrometry analysis. Journal of biomedicine & biotechnology 2012, 2012:985020.
34. Liu W., Gao X., Cai Q., Li J., Zhu Z., Li C., et al. Identification of novel serum biomarkers for gastric cancer by magnetic bead. Front Biosci (Elite Ed) 2010, 2:961-971.
35. Ebert M.P., Niemeyer D., Deininger S.O., Wex T., Knippig C., Hoffmann J., et al. Identification and confirmation of increased fibrinopeptide a serum protein levels in gastric cancer sera by magnet bead assisted MALDI-TOF mass spectrometry. Journal of proteome research 2006, 5:2152-2158.
36. Aebersold R., Goodlett D.R. Mass spectrometry in proteomics. Chem Rev 2001, 101:269-295.
37. Smith R.D., Loo J.A., Edmonds C.G., Barinaga C.J., Udseth H.R. New developments in biochemical mass spectrometry: electrospray ionization. Anal Chem 1990, 62:882-899.
38. Adkins J.N., Varnum S.M., Auberry K.J., Moore R.J., Angell N.H., Smith R.D., et al. Toward a human blood serum proteome: analysis by multidimensional separation coupled with mass spectrometry. Molecular & cellular proteomics : MCP 2002, 1:947-955.
39. Loei H., Tan H.T., Lim T.K., Lim K.H., So J.B., Yeoh K.G., et al. Mining the gastric cancer secretome: identification of GRN as a potential diagnostic marker for early gastric cancer. Journal of proteome research 2012, 11:1759-1772.
40. Liu C., Pan C., Liang Y. Screening and identification of serum proteomic biomarkers for gastric adenocarcinoma. Exp Ther Med 2012, 3:1005-1009.
41. Rohner T.C., Staab D., Stoeckli M. MALDI mass spectrometric imaging of biological tissue sections. Mech Ageing Dev 2005, 126:177-185.
42. Lay J.O. MALDI-TOF mass spectrometry of bacteria. Mass Spectrom Rev 2001, 20:172-194.
43. Szpunar J. Advances in analytical methodology for bioinorganic speciation analysis: metallomics, metalloproteomics and heteroatom-tagged proteomics and metabolomics. Analyst 2005, 130:442-465.
44. Demirev P.A., Ramirez J., Fenselau C. Tandem mass spectrometry of intact proteins for characterization of biomarkers from Bacillus cereus T spores. Anal Chem 2001, 73:5725-5731.
45. Erny G.L., Cifuentes A. Simplified 2-D CE-MS mapping: analysis of proteolytic digests. Electrophoresis 2007, 28:1335-1344.
46. Kersey P.J., Duarte J., Williams A., Karavidopoulou Y., Birney E., Apweiler R. The International Protein Index: an integrated database for proteomics experiments. Proteomics 2004, 4:1985-1988.
47. UniProt C. Reorganizing the protein space at the Universal Protein Resource (UniProt). Nucleic Acids Res 2012, 40:D71-D75.
48. Flicek P., Amode M.R., Barrell D., Beal K., Brent S., Carvalho-Silva D., et al. Ensembl 2012. Nucleic acids research 2012, 40:D84-90.
49. Pruitt K.D., Tatusova T., Brown G.R., Maglott D.R. NCBI Reference Sequences (RefSeq): current status, new features and genome annotation policy. Nucleic Acids Res 2012, 40:D130-D135.
50. Nakamura Y., Cochrane G., Karsch-Mizrachi I., International Nucleotide Sequence Database C The international nucleotide sequence database collaboration. Nucleic Acids Res 2013, 41:D21-D24.
51. Shilov I.V., Seymour S.L., Patel A.A., Loboda A., Tang W.H., Keating S.P., et al. The Paragon Algorithm, a next generation search engine that uses sequence temperature values and feature probabilities to identify peptides from tandem mass spectra. Molecular & cellular proteomics : MCP 2007, 6:1638-1655.
52. Tammen H., Schulte I., Hess R., Menzel C., Kellmann M., Schulz-Knappe P. Prerequisites for peptidomic analysis of blood samples: I. Evaluation of blood specimen qualities and determination of technical performance characteristics. Comb Chem High Throughput Screen 2005, 8:725-733.
53. Adam B.L., Qu Y., Davis J.W., Ward M.D., Clements M.A., Cazares L.H., et al. Serum protein fingerprinting coupled with a pattern-matching algorithm distinguishes prostate cancer from benign prostate hyperplasia and healthy men. Cancer research 2002, 62:3609-3614.
54. Vlahou A., Schellhammer P.F., Mendrinos S., Patel K., Kondylis F.I., Gong L., et al. Development of a novel proteomic approach for the detection of transitional cell carcinoma of the bladder in urine. The American journal of pathology 2001, 158:1491-1502.
55. Ransohoff D.F. Bias as a threat to the validity of cancer molecular-marker research. Nat Rev Cancer 2005, 5:142-149.
56. Ransohoff D.F. Lessons from controversy: ovarian cancer screening and serum proteomics. J Natl Cancer Inst 2005, 97:315-319.
57. Croswell J.M., Ransohoff D.F., Kramer B.S. Principles of cancer screening: lessons from history and study design issues. Semin Oncol 2010, 37:202-215.
58. Tammen H., Hess R., Schulte I., Kellmann M., Appel A., Budde P., et al. Prerequisites for peptidomic analysis of blood samples: II. Analysis of human plasma after oral glucose challenge -- a proof of concept. Combinatorial chemistry & high throughput screening 2005, 8:735-741.
59. Omenn G.S., States D.J., Adamski M., Blackwell T.W., Menon R., Hermjakob H., et al. Overview of the HUPO Plasma Proteome Project: results from the pilot phase with 35 collaborating laboratories and multiple analytical groups, generating a core dataset of 3020 proteins and a publicly-available database. Proteomics 2005, 5:3226-3245.
60. Cho S.Y., Lee E.Y., Lee J.S., Kim H.Y., Park J.M., Kwon M.S., et al. Efficient prefractionation of low-abundance proteins in human plasma and construction of a two-dimensional map. Proteomics 2005, 5:3386-3396.
61. Pieper R., Gatlin C.L., Makusky A.J., Russo P.S., Schatz C.R., Miller S.S., et al. The human serum proteome: display of nearly 3700 chromatographically separated protein spots on two-dimensional electrophoresis gels and identification of 325 distinct proteins. Proteomics 2003, 3:1345-1364.
62. Granger J., Siddiqui J., Copeland S., Remick D. Albumin depletion of human plasma also removes low abundance proteins including the cytokines. Proteomics 2005, 5:4713-4718.
63. Bonetta L. Protein purification: target identification. Nature 2006, 439:1021.
64. Huang L., Harvie G., Feitelson J.S., Gramatikoff K., Herold D.A., Allen D.L., et al. Immunoaffinity separation of plasma proteins by IgY microbeads: meeting the needs of proteomic sample preparation and analysis. Proteomics 2005, 5:3314-3328.
65. Dijkstra M., Vonk R.J., Jansen R.C. SELDI-TOF mass spectra: a view on sources of variation. Biomedical and Life Sciences J Chromatogr B Anal Technol Biomed Life Sci 2007, 847:12-23.
66. Diamandis E.P. Re: diagnostic potential of serum proteomic patterns in prostate cancer. J Urol 2004, 171:1244-1245. [author reply 1124-1245-1264.].
67. Garber K. Debate rages over proteomic patterns. J Natl Cancer Inst 2004, 96:816-818.
68. Qiu F.M., Yu J.K., Chen Y.D., Jin Q.F., Sui M.H., Huang J. Mining novel biomarkers for prognosis of gastric cancer with serum proteomics. J Exp Clin Cancer Res 2009, 28:126.
69. Helgason H.H., Engwegen J.Y., Zapatka M., Cats A., Boot H., Beijnen J.H., et al. Serum proteomics and disease-specific biomarkers of patients with advanced gastric cancer. Oncology letters 2010, 1:327-333.
70. Chong P.K., Lee H., Loh M.C., Choong L.Y., Lin Q., So J.B., et al. Upregulation of plasma C9 protein in gastric cancer patients. Proteomics 2010, 10:3210-3221.
71. Chong P.K., Lee H., Zhou J., Liu S.C., Loh M.C., Wang T.T., et al. ITIH3 is a potential biomarker for early detection of gastric cancer. Journal of proteome research 2010, 9:3671-3679.
72. Umemura H., Togawa A., Sogawa K., Satoh M., Mogushi K., Nishimura M., et al. Identification of a high molecular weight kininogen fragment as a marker for early gastric cancer by serum proteome analysis. Journal of gastroenterology 2011, 46:577-585.
73. Cohen M., Yossef R., Erez T., Kugel A., Welt M., Karpasas M.M., et al. Serum apolipoproteins C-I and C-III are reduced in stomach cancer patients: results from MALDI-based peptidome and immuno-based clinical assays. PloS one 2011, 6:e14540.
74. Fan N.J., Li K., Liu Q.Y., Wang X.L., Hu L., Li J.T., et al. Identification of tubulin beta chain, thymosin beta-4-like protein 3, and cytochrome b-c(1) complex subunit 1 as serological diagnostic biomarkers of gastric cancer. Clinical biochemistry 2013, 46:1578-1584.
75. Gomes C., Almeida A., Ferreira J.A., Silva L., Santos-Sousa H., Pinto-de-Sousa J., et al. Glycoproteomic analysis of serum from patients with gastric precancerous lesions. Journal of proteome research 2013, 12:1454-1466.